{"id":289,"date":"2020-06-01T10:00:00","date_gmt":"2020-06-01T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=289"},"modified":"2025-09-10T10:47:50","modified_gmt":"2025-09-10T10:47:50","slug":"china-bd-2020-jacobio-and-abbvie-enters-a-license-on-shp2-inhibitors-portfolio","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2020\/289.html","title":{"rendered":"[China BD 2020] Jacobio and Abbvie enters a License on SHP2\u00a0inhibitors portfolio"},"content":{"rendered":"\n<p>Announced Date: 2020-06-01 (June 1, 2020)<\/p>\n\n\n\n<p>Asset Name: JAB-3068 and JAB-3312<\/p>\n\n\n\n<p>Licensor (Seller): Jacobio Pharmaceuticals (China)<\/p>\n\n\n\n<p>Licensee (Buyer): AbbVie<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Small Molecule<\/p>\n\n\n\n<p>Asset Target: SHP2\u00a0inhibitors<\/p>\n\n\n\n<p>Potential Indication: solid tumor<\/p>\n\n\n\n<p>Stage until the deal: early clinical stage<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>AbbVie will be granted an exclusive license to the\u00a0SHP2\u00a0portfolio. Jacobio will continue to conduct early global clinical trials of JAB-3068 and JAB-3312 with AbbVie covering R&amp;D expenses. Upon completion, AbbVie will assume global development and commercialization responsibilities. Jacobio has an option, exercisable before the initiation of registrational trials, to exclusively develop and commercialize the\u00a0SHP2\u00a0program in mainland\u00a0China,\u00a0Hong Kong, and\u00a0Macau. <\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail:<\/p>\n\n\n\n<p>Jacobio will receive<\/p>\n\n\n\n<p>Upfront payment of\u00a0$45 million,<\/p>\n\n\n\n<p>Development, commercial milestone payments up to $ 855 million.<\/p>\n\n\n\n<p>Tiered royalties on net sales.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/news.abbvie.com\/2020-06-01-AbbVie-and-Jacobio-Announce-Strategic-Collaboration-to-Advance-SHP2-Inhibitors\">AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors &#8211; Jun 1, 2020<\/a><\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Note:<\/p>\n\n\n\n<p>Chinese Name of \u201cJacobio\u201c\uff0c\u52a0\u79d1\u601d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2020-06-01 (June 1, 2020) Asset Name: JAB-3068 and JAB-3312 Licensor (Seller): Jacobio Pharmaceuticals (China) &hellip; <a title=\"[China BD 2020] Jacobio and Abbvie enters a License on SHP2\u00a0inhibitors portfolio\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2020\/289.html\"><span class=\"screen-reader-text\">[China BD 2020] Jacobio and Abbvie enters a License on SHP2\u00a0inhibitors portfolio<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-289","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=289"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/289\/revisions"}],"predecessor-version":[{"id":290,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/289\/revisions\/290"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}